Association Between Non-alcoholic Fatty Liver Disease and Iron Status

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that low iron storages protects from and down-grades non-alcoholic fatty liver disease.

The aim of the study is to show the association between the severity of Non-alcoholic fatty liver disease to low iron status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease

NCT03986684

Nonalcoholic Fatty Liver Metabolic Syndrome

COMPLETED

Kinetics of Metabolic Cofactors in NAFLD

NCT03838822

Healthy

COMPLETED EARLY_PHASE1

Lifestyle Intervention in Fatty Liver (NAFLD)

NCT03354247

Non-Alcoholic Fatty Liver Disease

UNKNOWN NA

The Tailgate Study: A Pilot Study Measuring the Impact of Acute Alcohol Intake on Intrahepatic Lipid

NCT02141880

Obesity

COMPLETED

Effects of Dietary Nutrients on Liver and Adipose Tissue Metabolism

NCT03090347

NAFLD Nutrient; Excess

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients that will pass a CT scan that includes the abdomen will be asked to participate at our study. These patients will be divided into two groups - with and w/o fatty liver. The severity of fatty liver will be determined using the CT scan (as well as other parameters, such as the size of subcutaneous fat layer). Within 72 hours from the scan, a venous blood test will be taken from the enrolled patients (together with a BMI calculation and a blood pressure measurements). In the blood test we will examine liver functions, iron status etc.

This is a preliminary study that will aid in planning future strategies to treat or even prevent fatty liver (one of the epidemics of our century).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NAFLD - Non Alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non alcoholic fatty liver disease

blood analysis

Intervention Type PROCEDURE

A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)

control

blood analysis

Intervention Type PROCEDURE

A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood analysis

A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age\>18
* BMI\>25

Exclusion Criteria

* pregnancy
* unable to sign an informed consent (legally)
* known solid/hematological malignancy
* hemoglobinopathy or myelodysplastic disease (not including G6PD deficiency)
* active or carrier of viral hepatitis
* treated a drug the cause fatty liver (eg. amiodarone, tetracyclin, HAART, steroid treatment \> 3 months)
* consumption of \> 120g ethanol per week
* primary liver disease (eg. glycogen storage disease)
* CRP\>20
* acute intoxication
* surgery in previous 7 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No